Literature DB >> 16095481

Atypical neuroleptic malignant syndrome caused by olanzapine.

J Nielsen1, A M Bruhn.   

Abstract

OBJECTIVE: Neuroleptic malignant syndrome (NMS) is a rare syndrome with four main symptoms: rigidity, hyperthermia, altered mental status and autonomic instability. We report a patient with an atypical manifestation of NMS.
METHOD: A single case was reported.
RESULTS: A patient with pneumonia developed delirium and was treated with olanzapine and developed a NMS with fluctuating hyperthermia and autonomic instability during a month. Only slight rigidity was present. Creatine kinase was not elevated. The patient was severely agitated and manic. After discontinuation of olanzapine the patient showed no psychopathology or hyperthermia.
CONCLUSION: NMS should be considered when patients treated with antipsychotics develop one or more symptoms of NMS. Copyright (c) 2005 Blackwell Munksgaard

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16095481     DOI: 10.1111/j.1600-0447.2005.00578.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  11 in total

1.  Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa.

Authors:  Hasret Ayyıldız; Şenol Turan; Didem Gülcü; Cana Aksoy Poyraz; Esra Pehlivanoğlu; Fügen Çullu; Mehmet Kemal Arıkan
Journal:  Eat Weight Disord       Date:  2015-11-25       Impact factor: 4.652

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals.

Authors:  Rina P Patel; Meredith Gambrell; Theodore Speroff; Theresa A Scott; Brenda T Pun; Joyce Okahashi; Cayce Strength; Pratik Pandharipande; Timothy D Girard; Hayley Burgess; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

4.  Olanzapine-Induced Malignant Neuroleptic Syndrome.

Authors:  Tuba Berra Sarıtaş; Barış Çankaya; Alper Yosunkaya
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-07-09

5.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

Review 6.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

Authors:  Enasio Morris; Digby Green; Andis Graudins
Journal:  J Med Toxicol       Date:  2009-03

8.  A rare case of neuroleptic malignant syndrome without elevated serum creatine kinase.

Authors:  Koichi Nisijima; Katutoshi Shioda
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-24       Impact factor: 2.570

Review 9.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

10.  Olanzapine-Induced Neuroleptic Malignant Syndrome.

Authors:  Seyedhamze Hosseini; Forouzan Elyasi
Journal:  Iran J Med Sci       Date:  2017-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.